Combined intravitreal bevacizumab and photodynamic therapy for neovascular age-related macular degeneration

Markus S. Ladewig, Stefanie E. Karl, Victoria Hamelmann, Hans Martin Helb, Hendrik P.N. Scholl, Frank G. Holz, Nicole Eter

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Our aim was to evaluate the short-term safety and efficacy of combined photodynamic therapy (PDT) with verteporfin and intravitreal bevacizumab in neovascular age-related macular degeneration (AMD). Methods: A prospective non-randomized interventional case series of 30 eyes of 30 patients with choroidal neovascularization (CNV) caused by AMD was studied. All patients were treated with PDT followed by an intravitreal injection of bevacizumab (1.5 mg) on the same day. Ophthalmic evaluations included determination of best-corrected visual acuity by using ETDRS charts. CNV lesion characteristics were determined by fluorescein angiography, and retinal morphology by optical coherence tomography. Review examinations were performed 1, 4, and 12 weeks following treatment. Results: The median ETDRS letter scores increased by 3 letters after 4 weeks and 4.3 letters after 12 weeks. Median central retinal thickness decreased from the baseline by 145 μm (week 1), 205 μm (week 4), and 171 μm (week 12), respectively (P<0.0001, for all comparisons). One patient experienced a transient moderate vision loss after 4 weeks post treatment. Leakage on fluorescein angiography was resolved in all patients at week 12. No significant ocular or systemic side-effects were observed. Conclusions: Short-term results suggest that a single PDT in combination with intravitreal bevacizumab is safe and associated with stabilization of visual acuity and decrease of intraretinal and subretinal fluid accumulation in the macula. Further evaluation of this treatment strategy for neovascular AMD appears warranted.

Original languageEnglish (US)
Pages (from-to)17-25
Number of pages9
JournalGraefe's Archive for Clinical and Experimental Ophthalmology
Volume246
Issue number1
DOIs
StatePublished - Jan 2008

Keywords

  • AMD
  • Age-related macular degeneration
  • Bevacizumab
  • CNV
  • Eye
  • PDT
  • Photodynamic therapy
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Fingerprint Dive into the research topics of 'Combined intravitreal bevacizumab and photodynamic therapy for neovascular age-related macular degeneration'. Together they form a unique fingerprint.

Cite this